Clinical Trial Applications - Approved: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | Date Approved | |
|---|---|---|---|---|---|
1. |
ECCT/26/05/01 | C1091009 Study site 1193 Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants |
Principal Investigator(s) 1. Janet Nyawira Oyieko Site(s) in Kenya 1. KEMRI Butere Clinical Research Centre (Kakamega county) 2. Kenya Medical Research Institute Walter Reed Project (Kericho county) 3. Kenya Medical Research Institute (KEMRI) - Centre for Global Health Research (Kisumu county) 4. Victoria Biomedical Research Institute Kisumu County Referral Hospital (Kisumu county) |
08-11-2026 |
View |
2. |
ECCT/26/06/03 | C1091009 - Study Site 1254 Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants |
Principal Investigator(s) 1. Fredrick Kipyego Sawe Site(s) in Kenya 1. Kenya Medical Research Institute Walter Reed Project (Kericho county) 2. KEMRI Butere Clinical Research Centre (Kakamega county) 3. Kenya Medical Research Institute (KEMRI) - Centre for Global Health Research (Kisumu county) 4. Victoria Biomedical Research Institute Kisumu County Referral Hospital (Kisumu county) |
08-11-2026 |
View |
3. |
ECCT/26/03/03 | LIBRA A 52-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group, group sequential, Phase 3 study to evaluate the efficacy and safety of rilzabrutinib in patients aged 10 to 65 years with sickle-cell disease (LIBRA) |
Principal Investigator(s) 1. Jessie Githanga Site(s) in Kenya Getrudes’s Children\'s Hospital |
23-10-2026 |
View |
4. |
ECCT/26/06/02 | HibiscusJr A global phase 3 Randomised, Double-blind and Placebo-controlled Study Evaluating the Efficacy and Safety of etavopivat in children with Sickle Cell Disease. |
Principal Investigator(s) 1. Dr. Sharon Mokeira Ocharo Site(s) in Kenya 1. Victoria Biomedical Research Institute (Kisumu county) |
23-10-2026 |
View |
5. |
ECCT/26/04/01 | ACRN-MNK02-301 A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG ®) versus placebo on weight gain in underweight infants. |
Principal Investigator(s) 1. Prof. Videlis Nduba Site(s) in Kenya 1. KEMRI-CRDR (Nairobi City county) 2. KEMRI-MTWAPA (Kilifi county) 3. Moi University Clinical Research Centre (Uasin Gishu county) |
21-10-2026 |
View |
6. |
ECCT/26/02/03 | REVIVE Study - KNH A randomised, double blinded, placebo-controlled, multicentre trial of azithromycin prophylaxis for advanced HIV disease |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Kenyatta National Hospital (KNH) (Nairobi City county) |
28-09-2026 |
View |
7. |
ECCT/26/03/01 | C1091009 Study A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Trial to Evaluate the Safety, Tolerability, and Immunogenicity of a Multivalent Group B Streptococcus Vaccine in Healthy Pregnant Women and Their Infants |
Principal Investigator(s) 1. Lucas Otieno Tina Site(s) in Kenya 1. Victoria Biomedical Research Institute Kisumu County Referral Hospital (Kisumu county) 2. KEMRI Butere Clinical Research Centre (Kakamega county) 3. Kenya Medical Research Institute Walter Reed Project (Kericho county) 4. Kenya Medical Research Institute (KEMRI) - Centre for Global Health Research (Kisumu county) |
26-08-2026 |
View |
8. |
ECCT/26/02/02 | REVIVE Study - JOOTRH A randomised, double blinded, placebo-controlled, multicentre trial of azithromycin prophylaxis for advanced HIV disease |
Principal Investigator(s) 1. Loice Achieng Ombajo Site(s) in Kenya 1. Jaramogi Oginga Odinga Teaching and Referral Hospital (JOOTRH) (Kisumu county) |
22-08-2026 |
View |
9. |
ECCT/25/11/04 | Bifin02 and LGG® A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Charity Wambui Kanyoro Site(s) in Kenya 1. Moi University Clinical Research (Uasin Gishu county) 2. Kenya Medical Research Institute (KEMRI) CRDR Off Raila Odinga, Nairobi Kenya (Nairobi City county) 3. Kenya Medical Research Institute (KEMRI) Mwtapa (Kilifi county) |
19-08-2026 |
View |
10. |
ECCT/25/11/01 | COMBO-CONSTELLATION A Phase 3, randomized, double-blind, placebo-controlled trial to evaluate the effect of Bifidobacterium longum subsp. infantis DSM33361(Bifin02) administered together with Lacticaseibacillus rhamnosus GG DSM33156 (LGG®) versus placebo on weight gain in underweight infants |
Principal Investigator(s) 1. Dr. Wilson Muraya Site(s) in Kenya 1. KENYA MEDICAL RESEARCH INSTITUTE- MTWAPA (Kilifi county) 2. Moi University Clinical Research Centre-MUCRU (Uasin Gishu county) 3. Kenya Medical Research Institute (KEMRI) CRDR (Nairobi City county) |
21-06-2026 |
View |